Feedback PLC Directorate Change (7869E)
06 November 2015 - 8:01AM
UK Regulatory
TIDMFDBK
RNS Number : 7869E
Feedback PLC
06 November 2015
6 November 2015
Feedback plc
("Feedback" or the "Company")
Directorate Change
Further to the publication of Feedback's final results earlier
today, the Company announces the appointment to the Board of Dr
Balaji Ganeshan, Mike Hayball and Dr Alex Menys.
Disclosures under Schedule 2 of the AIM Rules
Dr Ganeshan, aged 33, holds or has held the following
directorships and/or partnerships in the previous five years:
Present Directorships/Partnerships Past Directorships/Partnerships
TexRad Limited -
Cambridge Computed Imaging
Limited
Stone Checker Software
Ltd
Prostate Checker Ltd
Dr Ganeshan holds 2,860,000 ordinary shares in the Company,
equivalent to 1.40% of the issued ordinary share capital of the
Company and 3,575,000 warrants of which, 715,000 warrants are
exercisable at a price of 1.25p per share and the remaining
2,860,000 are exercisable at 3p per share.
No additional information relating to Dr Ganeshan is required to
be disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM
Rules for Companies.
Michael Peter Hayball, aged 48, holds or has held the following
directorships and/or partnerships in the previous five years:
Present Directorships/Partnerships Past Directorships/Partnerships
Cambridge Computed Imaging -
Limited
TexRad Limited
Mr Hayball holds 5,670,000 ordinary shares in the Company,
equivalent to 2.78% of the issued ordinary share capital of the
Company and 5,200,000 options of which, 1,200,000 options are
exercisable at a price of 1.25p per share, 2,000,000 may be
exercised at 3p per share and the remaining 2,000,000 options are
exercisable at 5p per share.
No additional information relating to Mr Hayball is required to
be disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM
Rules for Companies.
Dr Alexander Henry Menys, aged 29, holds or has held the
following directorships and/or partnerships in the previous five
years:
Present Directorships/Partnerships Past Directorships/Partnerships
Motilent Limited -
Dr Menys does not hold any ordinary shares in the Company.
No additional information relating to Dr Menys is required to be
disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM
Rules for Companies.
For further information contact:
Feedback plc Tel: 01954
718072
Tom Charlton/ Trevor Brown
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging Biomarker') in confident decision-making: assessing
the prognosis, disease severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'. TexRAD is
manufactured under licence by the ISO 13485 certified company
Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More
information is available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABABBTMBTMTFA
(END) Dow Jones Newswires
November 06, 2015 02:01 ET (07:01 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024